新型糖尿病治疗药物:德谷胰岛素利拉鲁肽注射液  

New drug for the treatment of diabetes mellitus:Insulin Degludec&Liraglutide injection

作　　者：母义明[1] 胡蓓[2] MU Yi-ming;HU Pei(Department of Endocrinology,Chinese People's Liberation Army General Hospital,Beijing 100039,China;Clinical Pharmacology Research Center,Chinese Academy of Medical Sciences&Peking Union Medical College Hospital,Beijing 100032,China)

机构地区：[1]中国人民解放军总医院内分泌科,北京100039 [2]中国医学科学院北京协和医学院临床药理研究中心,北京100032

出　　处：《临床药物治疗杂志》2022年第6期16-20,共5页Clinical Medication Journal

摘　　要：德谷胰岛素利拉鲁肽注射液是全球首个基础胰岛素胰高糖素样肽-1受体激动剂注射液,也是糖尿病治疗领域首个新型生物制剂联合药物。其在分子基础上实现双受体激活;在作用机制上实现“协同互补,靶向调节”、在临床治疗上实现“增效减副,综合获益”。本文对德谷胰岛素利拉鲁肽注射液的创新点及其临床数据进行梳理,旨在论证其创新性和临床价值。Insulin Degludec&Liraglutide injection is the first basal insulin&glucagon-like peptide-1 receptor agonist injection,and also is the first new biological agent combination drug in the field of diabetes.It can activate double receptors on a molecular basis;can achieve synergistic and complementarity,as well as regulate target in the mechanism field;and can increase efficiency and reduce side effects,so as to get comprehensive benefits in clinical treatment.This article sorts out the innovations and clinical data of Insulin Degludec&Liraglutide injection,aims to demonstrate its innovation and clinical value,and helps to achieve high-quality diabetes blood glucose management,in order to improve the current situation of diabetes treatment in china.

关 键 词：德谷胰岛素利拉鲁肽注射液 糖尿病 基础胰岛素 胰高糖素样肽-1受体激动剂 

分 类 号：R978.1[医药卫生—药品]